Preliminary experience with Mitolactol in advanced tumors of the orofacial region and the larynx.
Mitolactol (Dibromodulcitol "DBD"; RlobromolR) an alkylating agent was applied in a clinical series of twenty advanced or relapsing cases of malignant tumors of the orofacial region and the larynx. It was administered orally in a mean total dose of 127 mg/kg/30 days. In 45% of the patients the treatment resulted in a diminution of tumors by more than 50%, with remission lasting 1-4 months. 30% of the patients responded by a retreat of the tumor volume smaller than 50%, while no therapeutic effect was noted in 25% of the patients, or the objective finding proved to be worse. Subsequent radiotherapy improved the results, and remissions which followed combined chemo-radiotherapy were prolonged up to 9 months. The effect of DBD treatment proved better in orofacial than in laryngeal carcinoma.
D000328:Adult; D000368:Aged; D001835:Body Weight / Q000187:drug effects; D004341:Drug Evaluation; D005153:Facial Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D007818:Laryngeal Diseases / Q000139:chemically induced; D007822:Laryngeal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D008936:Mitolactol / Q000009:adverse effects / Q000627:therapeutic use*; D009062:Mouth Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D012008:Recurrence; D012075:Remission, Spontaneous
D008936:Mitolactol